Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26878 | 0.97 | — | — | |
| SCHEMBL30068488 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL30294929 | 0.94 | GOT1 (0.46) | GOT1NOS3NOS2NOS1PI4KA | |
| Hydrochloric Acid SCHEMBL4709475 | 0.94 | GOT1 (0.46) | GOT1NOS3NOS2NOS1PI4KA | |
| SCHEMBL30711694 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL753209 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL3974934 | 0.94 | — | — | |
| Hydrazine SCHEMBL11032075 | 0.94 | — | — | |
| Biphenyl SCHEMBL27923035 | 0.91 | ASIC3 (0.43) | GOT1NOS3NOS2NOS1PI4KA | |
| Acetic Acid SCHEMBL28012854 | 0.87 | P2RX7 (0.44) | GOT1NOS3NOS2NOS1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791116-B2 | Myosin light chain kinase inhibitor compounds, compositions and related methods of use | NORTHWESTERN UNIVERSITY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130029999-A1 | MYOSIN LIGHT CHAIN KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND RELATED METHODS OF USE | NORTHWESTERN UNIVERSITY (US) | 2013-01-31 | — | — | US | disclosed |
| US-8278305-B2 | Myosin light chain kinase inhibitor compounds, compositions and related methods of use | NORTHWESTERN UNIVERSITY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100240668-A1 | Myosin Light Chain Kinase Inhibitor Compounds, Compositions and Related Methods of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-23 | — | — | US | disclosed |
| US-7732445-B2 | Myosin light chain kinase inhibitor compounds, compostions and related methods of use | NORTHWESTERN UNIVERSITY (US) | 2010-06-08 | — | — | US | disclosed |
| WO-2008011176-A9 | MYOSIN LIGHT CHAIN KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND RELATED METHODS OF USE | UNIV NORTHWESTERN (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008011176-A2 | MYOSIN LIGHT CHAIN KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND RELATED METHODS OF USE | NORTHWESTERN UNIVERSITY (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021035-A1 | Myosin light chain kinase inhibitor compounds, compostions and related methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029999-A1 | MYOSIN LIGHT CHAIN KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND RELATED METHODS OF USE | MYLK, MYLK2, MYLK3 | GOT1 3030/4885NOS3 3501/4885NOS2 3833/4885 |
| US-20080021035-A1 | Myosin light chain kinase inhibitor compounds, compostions and related methods of use | MYLK, MYLK3, MYLK2 | GOT1 3847/4885NOS3 2441/4885NOS2 2662/4885 |
| US-20100240668-A1 | Myosin Light Chain Kinase Inhibitor Compounds, Compositions and Related Methods of Use | MYLK, MYLK2, MYLK3 | GOT1 3030/4885NOS3 3501/4885NOS2 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.